Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial

Documenti analoghi

• NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS
  di: Goodman, A, et al.
  Pubblicazione: (2009)
• A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
  di: Folegatti, P, et al.
  Pubblicazione: (2021)
• Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
  di: Folegatti, PM, et al.
  Pubblicazione: (2020)
• Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
  di: Folegatti, P, et al.
  Pubblicazione: (2019)
• A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
  di: Pedro M. Folegatti, et al.
  Pubblicazione: (2021-07-01)